24 Participants Needed

Cell Therapies for Acute Myeloid Leukemia

Recruiting at 5 trial locations
CC
JB
CI
Overseen ByClinical Information
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Do I need to stop my current medications for the trial?

The trial protocol does not specify if you need to stop taking your current medications. However, it mentions that you should not use any anti-AML/MDS directed chemotherapy or targeted therapy (except hydroxyurea) within 14 days or 5 half-lives before leukapheresis, and no monoclonal antibodies within 28 days before leukapheresis.

What data supports the effectiveness of the treatment ARC-T Cells for Acute Myeloid Leukemia?

Research indicates that CD123-targeted therapies, like ARC-T Cells, show promise in treating acute myeloid leukemia (AML) due to their ability to target specific antigens on leukemia cells. However, challenges remain due to the overlap of these antigens with normal cells, which can lead to side effects.12345

Is the cell therapy for acute myeloid leukemia generally safe in humans?

Research on similar cell therapies for acute myeloid leukemia shows mixed safety results. Some studies indicate that certain therapies can target leukemia cells without harming normal cells, while others suggest potential risks of damaging normal blood-forming cells, which could lead to serious side effects.14678

How is the ARC-T Cells, SPRX002 treatment different from other treatments for acute myeloid leukemia?

The ARC-T Cells, SPRX002 treatment is unique because it uses engineered T cells that specifically target the CD123 antigen on leukemia cells, potentially reducing the risk of attacking normal cells. This approach aims to improve the precision and effectiveness of treatment compared to traditional therapies.1891011

What is the purpose of this trial?

The purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)

Research Team

TW

Tim Welliver, MD, PhD

Principal Investigator

Arcellx, Inc.

Eligibility Criteria

Adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), who have tried certain treatments without success, can join. They must be in good general health with proper organ function and not pregnant. People are excluded if they've had recent heart issues, other active cancers needing treatment, severe infections, autoimmune diseases, or a history of certain blood clots.

Inclusion Criteria

I have been diagnosed with a high-risk form of MDS with more than 10% bone marrow blasts.
I am fully active or can carry out light work.
My kidney and liver are working well according to my last tests.
See 3 more

Exclusion Criteria

My cancer has spread to my brain.
I have been treated with experimental gene or CAR-T therapy before.
I have been treated with targeted therapy for my cancer.
See 13 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Enrollment

Participants are enrolled into the study after meeting eligibility criteria

1 week

Pretreatment with Lymphodepletion Chemotherapy

Participants receive lymphodepletion chemotherapy prior to cell therapy

1 week

Treatment

Participants receive a single infusion of SPRX002 and ARC-T cells followed by regular administration of SPRX002

4 weeks
Weekly visits for monitoring

Treatment Extension

Continued administration of SPRX002 to assess long-term efficacy and safety

6 months
Monthly visits

Follow-up

Participants are monitored for safety and effectiveness after treatment

24 months
Monthly for 6 months, then quarterly

Long-term Safety Follow-up

Long-term safety data collection for up to 15 years as per health authority guidelines

15 years

Treatment Details

Interventions

  • ARC-T Cells
  • SPRX002
Trial Overview The trial is testing ARC-T cells and SPRX002 to see if they're safe and effective for patients whose AML or MDS hasn't responded to previous treatments. It's an early-phase study which means it's one of the first times these therapies are being tested in humans.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: CD123-Specific Adapter (SPRX002) and Universal CAR-Modified T Cell (ARC-T Cells)Experimental Treatment2 Interventions
Arm 1: Phase 1 Study of monovalent CD123-Specific Adapter (SPRX002) and Universal CAR-Modified T cell (ARC-T Cells) for the Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Find a Clinic Near You

Who Is Running the Clinical Trial?

Arcellx, Inc.

Lead Sponsor

Trials
5
Recruited
650+

Findings from Research

A novel method was developed to generate large numbers of reactive T-cell lines specifically targeting acute myeloid leukemia (AML), with an estimated frequency of 6 AML-reactive T cells per million peripheral blood mononuclear cells from patients.
These T-cell lines demonstrated the ability to specifically kill autologous AML cells and induce apoptosis, particularly through CD4(+) T cells, suggesting their potential for effective adoptive immunotherapy in AML treatment.
Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells.Zhong, RK., Lane, TA., Ball, ED.[2008]
B7-H3 is identified as a promising target for CAR T-cell therapy in acute myeloid leukemia (AML), as it is overexpressed on leukemic cells but not significantly on normal bone marrow progenitors, potentially reducing the risk of harming healthy cells.
B7-H3-specific CAR T-cells (B7-H3.CAR-T) demonstrated effective cytotoxicity against AML in both in vitro and patient-derived xenograft models, while showing a favorable safety profile with minimal hematopoietic toxicity.
Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.Lichtman, EI., Du, H., Shou, P., et al.[2022]
CAR T-cell therapy shows promise in improving outcomes for patients with acute myeloid leukemia (AML), a condition with historically poor prognosis.
A significant challenge for the effectiveness of CAR T-cell therapy in AML is the identification of specific target antigens on leukemia cells, as well as the risk of immune escape due to changes in these antigens and a suppressive tumor environment.
Current challenges for CAR T-cell therapy of acute myeloid leukemia.Sauer, T., Rooney, CM.[2020]

References

Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells. [2008]
Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. [2022]
Current challenges for CAR T-cell therapy of acute myeloid leukemia. [2020]
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. [2021]
Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond. [2020]
A modular and controllable T cell therapy platform for acute myeloid leukemia. [2023]
A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML. [2020]
Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia. [2022]
Acute myeloid leukemia therapeutics: CARs in the driver's seat. [2021]
10.United Statespubmed.ncbi.nlm.nih.gov
Employing Synthetic T-cell Biology to Target AML without On-Target/Off-Cancer Toxicity. [2023]
11.United Statespubmed.ncbi.nlm.nih.gov
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security